Equities analysts expect Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Rating) to announce sales of $15.48 million for the current fiscal quarter, according to Zacks. Five analysts have provided estimates for Mirum Pharmaceuticals’ earnings. The highest sales estimate is $19.49 million and the lowest is $13.60 million. Mirum Pharmaceuticals posted sales of $11.00 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 40.7%. The company is scheduled to issue its next earnings results on Monday, January 1st.
On average, analysts expect that Mirum Pharmaceuticals will report full-year sales of $69.77 million for the current financial year, with estimates ranging from $60.76 million to $83.23 million. For the next fiscal year, analysts expect that the business will post sales of $156.06 million, with estimates ranging from $142.40 million to $171.10 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow Mirum Pharmaceuticals.
Mirum Pharmaceuticals (NASDAQ:MIRM – Get Rating) last announced its earnings results on Thursday, May 5th. The company reported ($1.17) EPS for the quarter, beating analysts’ consensus estimates of ($1.39) by $0.22. Mirum Pharmaceuticals had a negative net margin of 218.74% and a negative return on equity of 163.01%. During the same period in the previous year, the business earned ($1.68) earnings per share.
NASDAQ MIRM opened at $24.76 on Friday. The stock has a market capitalization of $788.23 million, a P/E ratio of -10.96 and a beta of 1.23. Mirum Pharmaceuticals has a 52-week low of $12.82 and a 52-week high of $28.65. The firm has a 50-day moving average price of $24.52 and a 200 day moving average price of $20.28.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Polar Capital Holdings Plc acquired a new position in Mirum Pharmaceuticals during the first quarter worth about $21,441,000. Prosight Management LP acquired a new stake in shares of Mirum Pharmaceuticals in the first quarter valued at approximately $1,628,000. Rock Springs Capital Management LP grew its position in shares of Mirum Pharmaceuticals by 8.3% in the first quarter. Rock Springs Capital Management LP now owns 1,666,208 shares of the company’s stock valued at $36,690,000 after purchasing an additional 127,394 shares during the last quarter. Delphia USA Inc. acquired a new stake in shares of Mirum Pharmaceuticals in the first quarter valued at approximately $241,000. Finally, State Street Corp grew its position in shares of Mirum Pharmaceuticals by 7.3% in the first quarter. State Street Corp now owns 132,744 shares of the company’s stock valued at $2,923,000 after purchasing an additional 9,009 shares during the last quarter. Institutional investors own 87.68% of the company’s stock.
Mirum Pharmaceuticals Company Profile (Get Rating)
Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease.
- Get a free copy of the StockNews.com research report on Mirum Pharmaceuticals (MIRM)
- These Are the Three (3) Most Upgraded Stocks For Q2
- MarketBeat: Week in Review 5/23 – 5/27
- Short Sellers Provide Entry Into Hibbet, Inc At Rock Bottom Prices
- Affirm Stock Has Affirmed a Bottom
- Airbnb: Bold Competitive Threats & A New World of Travel
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.